Rauscher et al. found that in breast cancer NFE2L3 displays hypermethylation for estrogen receptor (ER)-positive tumors and hypomethylation for ER-negative tumors, and methylation level of its promoter region exhibits an inverse correlation with expression among the cancer samples [34]. The gene discussed is NFE2L3; the disease is cancer.